UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Registrant's telephone number, including area code: (617) 334-2805 Securities registered pursuant to Section 12(b) of the Act: | | | Name of each exchange on | | --- | --- | --- | | Title of each class | Trading Symbol(s) | which registered | | Units, each consisting of one Class A | NTWOU | The Nasdaq Stock Market LLC | | Ordinary Share and one-half of one | | | | Redeemable Warrant | | | | Class A Ordinary Shares, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 ( State or other jurisdiction of incorporation or organ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 ( State or other jurisdiction of incorporation or organ ...

Exhibit 99.1 Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption (IDE) approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025 Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...

Exhibit 99.1 Maui Land & Pineapple Company Reports Fiscal 2024 Results KAPALUA, Hawai'i / March 31, 2025 (BusinessWire) – Maui Land & Pineapple Company, Inc. (NYSE: MLP) today reported financial results covering the year ended December 31, 2024 and announced the date and time of their Annual Meeting of Stockholders, which will be held virtually on Wednesday, May 21, 2025, at 8:30 a.m., Hawai'i Standard Time, via conference call. "In 2024, our team made significant strides in implementing a strategic plan to ...

Business Operations and Strategy - Spruce Power operates approximately 85,000 home solar assets and customer contracts, generating revenues primarily through long-term customer agreements and third-party contracts for solar renewable energy credits[18]. - The company completed the acquisition of approximately 2,400 home solar assets from a regulated utility company, with an average remaining contract life of approximately 11 years[22]. - Following the NJR Acquisition, Spruce Power's portfolio consists of 14 portfolios of home solar assets with a combined capacity of approximately 514 MWdc[24]. - The average remaining contract term for home solar assets in Spruce Power's portfolio is approximately 11 years as of December 31, 2024[34]. - Spruce Power's corporate strategy focuses on subscription-based solutions for distributed energy resources, aiming to deliver predictable revenues and profits[25]. - The company has a dedicated M&A team that has successfully acquired high-quality portfolios of solar energy systems, minimizing customer acquisition costs[30]. - Spruce Power's portfolio is geographically diverse across 18 states in the U.S., reducing exposure to localized risks and providing stable cash flows[35]. - The company aims to grow customer revenues by focusing on channels with the lowest customer acquisition costs, including acquiring existing systems and selling additional services[26]. Financial Performance - For the year ended December 31, 2024, the company's revenues totaled $82.1 million, compared to $79.9 million for the year ended December 31, 2023, reflecting a year-over-year increase of approximately 2.8%[184]. - The net loss attributable to stockholders for the year ended December 31, 2024, was $70.5 million, compared to a net loss of $65.8 million for the previous year, indicating an increase in losses of approximately 10.7%[184]. - Revenues increased by $2.2 million, or 3%, to $82.1 million in 2024 compared to 2023, primarily due to increased PPA revenues from the Tredegar Acquisition[201]. - Total operating expenses rose by $15.8 million, or 14%, to $132.5 million in 2024, driven by increased costs in operations and maintenance, selling, general and administrative expenses, and impairment of goodwill[200]. - Impairment of goodwill increased by $28.8 million, or 100%, to $28.8 million in 2024 due to a continuous decline in stock price and market capitalization[206]. - Interest income increased to $22.8 million in 2024 from $19.5 million in 2023, attributed to a full year of interest from the SEMTH Master Lease[207]. - Interest expense, net decreased by $1.7 million, or 4%, to $40.2 million in 2024, primarily due to net realized gains from interest rate swaps[208]. - Working capital as of December 31, 2024, was $76.9 million, with cash and cash equivalents totaling $109.1 million[212]. - The company had a debt balance of $705.3 million as of December 31, 2024, all of which is non-recourse project-level debt[214]. - Net cash used in continuing operating activities was $(41.7) million in 2024, compared to $(31.7) million in 2023[216]. Market and Regulatory Environment - Federal, state, and local government incentives support the adoption of solar energy, allowing Spruce Power to lower prices for customers and enhance return on investment[49]. - The Inflation Reduction Act (IRA) enacted on August 16, 2022, includes significant policy initiatives to enhance the clean energy industry, but potential revisions or delays in funding could negatively impact the company's business[50]. - The solar energy industry is still developing, and the company faces competition from traditional energy companies and other renewable energy firms, which could adversely affect its business growth[63]. - The company is subject to various risks related to regulatory changes, legal proceedings, and compliance costs, which could adversely affect business operations[61]. - Regulatory challenges in various states may limit the company's ability to deliver solar energy and qualify for incentives, impacting growth opportunities[121]. - Changes in laws regarding rebates and net metering could reduce the attractiveness of solar energy systems, affecting customer acquisition[122]. - The evolving regulatory landscape concerning electricity pricing and competition with utilities may reduce demand for the company's solar energy systems[127]. - Adverse changes in solar-related policies could negatively impact the company's financial condition and operational results[128]. Risks and Challenges - The company is exposed to risks related to the performance and reliability of solar energy systems, which could lead to warranty claims and product liability issues, adversely impacting financial performance[67]. - A material reduction in the retail price of traditional utility-generated electricity could harm the company's financial condition and results of operations[58]. - Rising interest rates could adversely affect the company's financial condition, and the effectiveness of hedging strategies may be limited[58]. - The company faces significant risks related to climate change, which could adversely affect energy production and revenue generation from solar energy systems[71]. - The company typically bears the risk of loss and maintenance costs for solar energy systems, which could lead to unforeseen expenses if repairs exceed estimates[72]. - The company may experience a reduction in the residual value of solar energy systems at the end of customer agreements, potentially impairing financial performance[73]. - Tariffs and trade restrictions imposed by the U.S. government on solar products from China could increase costs and reduce competitive pricing capabilities[75]. - The company competes with traditional energy companies and vertically integrated solar companies, which may have greater resources and market advantages[77][78]. - There is a risk of increased customer credit defaults, particularly during economic downturns, which could adversely affect revenue and financial condition[104]. - The company faces significant fluctuations in customer demand, which could affect operating results and growth potential[95]. - The company may require additional financing to support growth strategies, and failure to secure such financing could adversely affect operations[88][90]. - The company does not have direct control over supplier costs for solar energy system components, which may hinder competitive pricing[91]. - The company faces challenges in managing growth effectively, which could impact customer service and operational efficiency[86]. Management and Governance - The recent CEO transition occurred on April 12, 2024, with Christopher Hayes appointed as President and CEO, which may create uncertainty and impact business operations[98]. - Management has limited experience in operating a public company, which may hinder effective growth management and compliance with regulatory obligations[99]. - The company is subject to risks associated with proxy contests and actions of activist stockholders, which can be costly and time-consuming, potentially disrupting operations[153]. - The company has a comprehensive cybersecurity risk management program integrated into its overall enterprise risk management framework, overseen by the Audit Committee[156]. - The Audit Committee receives quarterly reports on cybersecurity matters and related risk exposures, ensuring ongoing oversight[157]. - The ability to attract and retain qualified personnel is critical, as competition for skilled employees is intense, impacting the execution of business strategies[97]. Legal and Compliance Issues - The company agreed to a settlement amount of $19.5 million to resolve class action litigation, with a net payment of $15.0 million after insurance recoveries[115]. - The SEC imposed a civil money penalty of $11.0 million for violations of federal securities laws, which has been paid[117]. - The company is currently involved in multiple legal proceedings, which could result in significant costs and resource diversion[118]. - The company faces potential patent infringement claims that could materially affect its business and financial condition[120]. - The company has received subpoenas from state attorneys general regarding its business practices, which may result in fines or penalties[131]. - The company has identified material weaknesses in internal control over financial reporting, which could lead to inaccurate financial reporting and a decline in stock price[132][133]. - The company is subject to evolving laws and regulations related to data privacy and security, which could increase operational costs and impact business[130]. Shareholder and Stock Information - The average closing price of the company's common stock was below $1.00 per share for 30 consecutive trading days in 2022 and 2023, raising the risk of delisting from the NYSE[141]. - The company has the ability to issue up to 324,696,266 shares of common stock under its 2020 Equity Incentive Plan, which could dilute existing stockholders' interests[146]. - The company has no current plans to declare cash dividends, meaning investors may need to rely on share price appreciation for future gains[139]. - Clayton Capital Appreciation Fund, L.P. and its affiliates owned approximately 2.1% of the company's outstanding shares and nominated two candidates for election as directors at the 2024 Annual Meeting of Stockholders[152]. - The company entered into a Cooperation Agreement with Clayton, agreeing to increase the Board size from six to seven directors and appoint Clara Nagy McBane to the Board[152].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-K ___________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from January 1, 2024 to December 31, 2024 Commission file number 001-41959 ___________________________ SolarMax ...

Financial Performance - Fourth-quarter 2024 net income attributable to common stock totaled $274 million, $0.19 per share, and adjusted net income attributable to common stock totaled $450 million, $0.31 per share [2] - Net income attributable to common stockholders for 2024 was $1,889 million, compared to $1,848 million in 2023 [93] - Net income for 2024 was $4.399 billion, up from $3.751 billion in 2023, reflecting improved operational performance [98] - Adjusted net income attributable to common stock for 2024 was $2.146 billion, slightly down from $2.221 billion in 2023 [103] - FCX's consolidated income tax provision for 2024 shows an effective tax rate of 42% with a provision of $520 million, compared to 42% and $724 million in 2023 [108] - FCX estimates a consolidated effective tax rate of 40% for 2025, with tax impacts at 39% for Peru, 36% for Indonesia, and 0% for the U.S. [114] - Net income attributable to noncontrolling interests totaled $447 million in Q4 2024, representing 36% of FCX's consolidated income before taxes [129] - FCX estimates net income attributable to noncontrolling interests to approximate $2.3 billion for 2025, representing 35% of consolidated income before taxes [132] - Net income attributable to noncontrolling interests for Q4 2023 was $619 million, representing 36% of FCX's consolidated income before taxes [129] Production and Sales - Consolidated production in fourth-quarter 2024 totaled 1.04 billion pounds of copper, 432 thousand ounces of gold, and 22 million pounds of molybdenum [2] - Consolidated sales in fourth-quarter 2024 totaled 1.0 billion pounds of copper, 350 thousand ounces of gold, and 18 million pounds of molybdenum [2] - Consolidated sales for 2025 are expected to approximate 4.0 billion pounds of copper, 1.6 million ounces of gold, and 88 million pounds of molybdenum [2] - Incremental copper production from technology and leaching initiatives totaled 50 million pounds in fourth-quarter 2024 and 214 million pounds for the year 2024 [13] - FCX's North America copper sales for 2024 were 1.26 billion pounds, with an estimated 1.4 billion pounds for 2025 [21] - FCX's South America copper sales for 2024 were 1.2 billion pounds, with an expected 1.1 billion pounds for 2025 [30] - PT-FI's Kucing Liar deposit is expected to produce over 7 billion pounds of copper and 6 million ounces of gold between 2029 and 2041, with capital investments estimated at $4 billion over the next 7-8 years [39] - PT-FI's consolidated copper sales volumes in Q4 2024 were 376 million pounds, down from 511 million pounds in Q4 2023, primarily due to lower ore grades and shipment timing [45] - PT-FI's consolidated gold sales volumes in Q4 2024 were 343 thousand ounces, down from 544 thousand ounces in Q4 2023 [45] - PT-FI's projected sales volumes for 2025 are 1.55 billion pounds of copper and 1.6 million ounces of gold, reflecting reduced operating rates due to planned maintenance projects [46] - Copper production in Q4 2024 was 1,041 million recoverable pounds, with sales of 992 million pounds, compared to 1,095 million pounds produced and 1,116 million pounds sold in Q4 2023 [84] - Gold production in Q4 2024 was 432 thousand recoverable ounces, with sales of 350 thousand ounces, compared to 573 thousand ounces produced and 549 thousand ounces sold in Q4 2023 [84] - Molybdenum production in Q4 2024 was 22 million recoverable pounds, with sales of 18 million pounds, compared to 20 million pounds produced and 22 million pounds sold in Q4 2023 [84] - Total copper production for 2024 was 4,214 million recoverable pounds, slightly up from 4,212 million pounds in 2023 [87] - Gold production in 2024 was 1,880 thousand recoverable ounces, down from 1,993 thousand ounces in 2023 [87] - FCX's mined copper sales in 2024 were 45% in concentrate, 34% as cathode, and 21% as rod, with an average realized copper price of $4.15 per pound in Q4 2024 [118] - At December 31, 2024, FCX had provisionally priced copper sales totaling 133 million pounds at an average price of $3.96 per pound [125] - FCX's net deferred profits on inventories at Atlantic Copper totaled $181 million at December 31, 2024, to be recognized in future periods [127] - Silver sales in South America operations totaled 3.6 million ounces in 2024 at an average realized price of $29.35 per ounce [174] - Silver sales in South America operations totaled 4.1 million ounces in 2023 at an average realized price of $23.57 per ounce [177] - Silver sales in Q4 2024 were 1.4 million ounces at an average realized price of $29.85 per ounce [180] - Silver sales in Q4 2023 were 2.0 million ounces at an average realized price of $23.58 per ounce [183] - Silver sales in 2024 were 6.9 million ounces at an average realized price of $28.52 per ounce [186] - Silver sales in 2023 were 6.0 million ounces at an average realized price of $23.37 per ounce [190] - Molybdenum sales volume remained stable at 30 million recoverable pounds for both 2024 and 2023 [198] Costs and Expenses - Consolidated unit net cash costs for FCX's copper mines are expected to average $1.60 per pound of copper for the year 2025 [12] - Average unit net cash costs for North America copper mines were $3.04 per pound in Q4 2024, expected to approximate $3.00 per pound for 2025 [22][23] - Average unit net cash costs for South America operations were $2.36 per pound in Q4 2024, expected to approximate $2.50 per pound for 2025 [31][32] - PT-FI's unit net cash credits in Q4 2024 were $0.08 per pound of copper, favorable compared to less than $0.01 per pound in Q4 2023, primarily due to higher gold credits [47] - Production and delivery costs for 2024 were $15,554 million, up from $13,627 million in 2023 [93] - PT-FI's new smelter and precious metals refinery incurred $133 million in operational readiness and startup costs in 2024 [94] - Consolidated interest costs for 2024 were $710 million, down from $782 million in 2023 [94] - Total charges for feasibility and optimization studies were $62 million ($0.05 per pound of copper) and $60 million ($0.05 per pound of copper) for metals inventory adjustments [161] - Total charges for feasibility and optimization studies were $107 million ($0.08 per pound of copper) [166] - Nonrecurring charges of $97 million ($0.08 per pound of copper) were incurred in 2024 for labor-related charges at Cerro Verde [175] - Feasibility and optimization studies in 2024 resulted in charges of $57 million ($0.05 per pound of copper) [175] - Noncash and other costs for Indonesia operations in 2024 included $144 million for ARO adjustment and $133 million for operational readiness and startup costs [187] - Noncash and other costs for Indonesia operations in 2023 included $112 million in credits to correct historical PT-FI ARO model inputs and $55 million for an administrative fine [191] - Total costs for molybdenum mines increased to $630 million in 2024 from $530 million in 2023 [198] - Net cash costs for molybdenum mines rose to $535 million in 2024 from $448 million in 2023 [198] - DD&A expenses for molybdenum mines increased to $73 million in 2024 from $66 million in 2023 [198] - Noncash and other costs, net for molybdenum mines increased to $22 million in 2024 from $16 million in 2023 [198] Cash Flow and Capital Expenditures - Operating cash flows totaled $1.4 billion in fourth-quarter 2024 and $7.2 billion for the year 2024 [2] - Capital expenditures in fourth-quarter 2024 totaled $1.2 billion, including $0.6 billion for major mining projects and $0.2 billion for PT-FI's new smelter and precious metals refinery [2] - FCX generated operating cash flows of $1.4 billion in Q4 2024 and $7.2 billion for the full year 2024 [63] - FCX's consolidated operating cash flows for 2025 are estimated to approximate $6.2 billion, based on current sales volume and cost estimates [64] - Capital expenditures for 2025 are expected to approximate $5.0 billion, including $2.8 billion for major mining projects and $0.6 billion for PT-FI's new downstream processing facilities [66] - FCX had $3.9 billion in consolidated cash and cash equivalents at December 31, 2024, with $3.0 billion of availability under its revolving credit facility [62] - FCX's net debt at December 31, 2024, excluding $3.2 billion of debt for PT-FI's new downstream processing facilities, totaled $1.06 billion [71] - FCX declared a total cash dividend of $0.15 per share, consisting of a $0.075 quarterly base dividend and a $0.075 variable performance-based dividend, payable on February 3, 2025 [72] - FCX has 1.4 billion shares outstanding and $3.1 billion available under its share repurchase program as of January 22, 2025 [73] - Cash flow from operating activities rose to $7.160 billion in 2024, compared to $5.279 billion in 2023, indicating stronger cash generation [98] - Capital expenditures for Indonesia operations decreased to $2.908 billion in 2024 from $3.411 billion in 2023, reflecting reduced investment [98] - Net cash used in financing activities was $3.284 billion in 2024, up from $2.650 billion in 2023, driven by higher debt repayments and dividends [98] - FCX's net debt as of December 31, 2024, was $4.289 billion, excluding $3.233 billion for PT-FI's new downstream processing facilities [116] Prices and Realized Values - Average realized prices in fourth-quarter 2024 were $4.15 per pound for copper, $2,628 per ounce for gold, and $22.23 per pound for molybdenum [2] - The average realized price for copper in Q4 2024 was $4.15 per pound, up from $3.81 per pound in Q4 2023 [84] - The average realized price for gold in Q4 2024 was $2,628 per ounce, up from $2,034 per ounce in Q4 2023 [84] - The average realized price for molybdenum in Q4 2024 was $22.23 per pound, up from $20.66 per pound in Q4 2023 [84] - Average realized copper price per pound increased to $4.21 in 2024 from $3.85 in 2023 [87] - Gross profit per pound of molybdenum decreased to $2.04 in Q4 2024 from $2.48 in Q4 2023 [194] - Gross loss per pound of molybdenum was $0.39 in 2024, compared to a gross profit of $5.79 per pound in 2023 [198] Reserves and Assets - FCX's preliminary estimated consolidated recoverable proven and probable mineral reserves at December 31, 2024, include 97.0 billion pounds of copper, 23.0 million ounces of gold, and 3.16 billion pounds of molybdenum [54] - Total assets increased to $54.848 billion in 2024 from $52.506 billion in 2023, driven by growth in property, plant, and equipment [96] - Long-term debt increased to $8.907 billion in 2024 from $8.656 billion in 2023, indicating higher borrowing [96] - Restricted cash and cash equivalents decreased to $1.0 billion in 2024 from $1.3 billion in 2023, due to regulatory changes in Indonesia [96][99] - Total assets at December 31, 2024, were $54.848 billion, with Indonesia operations accounting for $27.309 billion [140] Segment Performance - North America Copper Mines generated $6,060 million in total revenues for the year ended December 31, 2024, with $180 million from unaffiliated customers and $5,880 million from intersegment sales [143] - South America Operations reported total revenues of $4,533 million for 2024, including $3,618 million from Cerro Verde and $915 million from other operations [143] - Indonesia Operations contributed $9,774 million in revenues for 2024, with $544 million from intersegment sales [143] - FCX's total operating income for 2024 was $6,864 million, with $5,622 million from Indonesia Operations and $1,471 million from South America Operations [143] - Capital expenditures for 2024 totaled $4,808 million, with $2,908 million allocated to Indonesia Operations and $1,033 million to North America Copper Mines [143] - North America Copper Mines revenues for Q4 2024 were $1.606 billion, with copper contributing $1.373 billion and molybdenum contributing $175 million [151] - Gross profit for North America Copper Mines in Q4 2024 was $183 million, with copper sales at 320 million recoverable pounds and molybdenum sales at 8 million recoverable pounds [151] - Unit net cash costs for copper in Q4 2024 were $3.04 per pound, while molybdenum unit net cash costs were $15.40 per pound [151] - North America Copper Mines revenues for Q4 2023 were $1.385 billion, with copper contributing $1.209 billion and molybdenum contributing $134 million [154] - Gross profit for North America Copper Mines in Q4 2023 was $128 million, with copper sales at 319 million recoverable pounds and molybdenum sales at 7 million recoverable pounds [154] - Unit net cash costs for copper in Q4 2023 were $2.86 per pound, while molybdenum unit net cash costs were $17.50 per pound [154] - North America Copper Mines revenues for the full year 2024 were $6.211 billion, with copper contributing $5.417 billion and molybdenum contributing $608 million [159] - Gross profit for North America Copper Mines in 2024 was $816 million, with copper sales at 1.263 billion recoverable pounds and molybdenum sales at 30 million recoverable pounds [159] - Unit net cash costs for copper in 2024 were $3.11 per pound, while molybdenum unit net cash costs were $16.20 per pound [159] - South America Operations revenues excluding adjustments were $1.312 billion for the three months ended December 31, 2024, with copper contributing $1.208 billion [167] - South America Operations gross profit was $314 million for the three months ended December 31, 2024, with copper accounting for $283 million [167] - South America Operations gross profit per pound of copper was $1.05 using the by-product method and $0.95 using the co-product method for the three months ended December 31, 2024 [167] - South America Operations revenues excluding adjustments were $1.175 billion for the three months ended December 31, 2023, with copper contributing $1.096 billion [170] - South America Operations gross profit was $181 million for the three months ended December 31, 2023, with copper accounting for $176 million [170] - South America Operations gross profit per pound of copper was $0.63 using the by-product method and $0.62 using the co-product method for the three months ended December 31, 2023 [170] - South America operations reported revenues of $5,171 million in 2024, with production and delivery costs of $3,230 million and DD&A of $446 million [174] - Other mining operations generated revenues of $26,406 million in 2024, with production and delivery costs of $18,012 million and DD&A of $1,737 million [174] - South America operations achieved gross profit of $1,492 million in 2024, with copper sales of 1,177 million recoverable pounds and gross profit per pound of $1.27 [174] - South America operations reported revenues of $4,941 million in 2023, with production and delivery costs of $3,239 million and DD&A of $459 million [177] - Other mining operations generated revenues of $24,166 million in 2023, with production and delivery costs of $16,406 million and DD&A of $1,545 million [177] - South America operations achieved gross profit of $1,241 million in 2023, with copper sales of 1,200 million recoverable pounds and gross profit per pound of $1.04 [177] - Indonesia operations product revenues for Q4 2024 were $2.492 billion, with copper contributing $1.543 billion and gold contributing $901 million [180] - Gross profit for Indonesia operations in Q4 2024 was $1.056 billion, with copper accounting for $638 million and gold for $396 million [180] - Copper sales in Q4 2024 were 376 million recoverable pounds, generating a gross profit of $2.81 per pound [180] - Gold sales in Q4 2024 were 343 thousand recoverable ounces, generating a gross profit of $1,153 per ounce [180] - Indonesia operations product revenues for Q4 2023 were $3.106 billion, with copper contributing $1.947 billion and gold contributing $1.108 billion [183] - Gross profit for Indonesia operations in Q4 2023 was $1.695 billion, with copper accounting for $1.054 billion and gold for $614 million [183] -

Exhibit 99.1 Seritage Growth Properties Reports Fourth Quarter and Full Year 2024 Operating Results New York – March 31, 2025 – Seritage Growth Properties (NYSE: SRG) (the "Company"), a national owner and developer of retail, residential and mixed-use properties today reported financial and operating results for the year ended December 31, 2024. "This quarter we have made strides to ready more assets for sale: signing critical leases, achieving partnership approvals, securing zoning and other important mile ...

Acquisition and Partnerships - The company acquired Lowell Therapeutics, Inc. for approximately $32.5 million, with up to $26.0 million in contingent consideration based on regulatory and sales milestones[25]. - The divestment of DSUVIA to Alora Pharmaceuticals in April 2023 includes royalties and sales-based milestones, while the company continues to market DSUVIA to the Department of Defense[43]. - The company has entered into an agreement with XOMA to sell rights to payments related to DSUVIA sales, providing funding for Niyad's development[44]. Product Development and Regulatory Approvals - Niyad™ has received an Investigational Device Exemption (IDE) and Breakthrough Device Designation from the FDA, with an ongoing registrational trial[26]. - The NEPHRO CRRT Study aims to enroll 70 adult patients and evaluate the efficacy of Niyad compared to placebo, focusing on mean post-filter activated clotting time[28]. - LTX-608 is being explored for indications including antiviral treatment and acute respiratory distress syndrome (ARDS), with initial studies showing potential benefits in COVID patients[29]. - The company is focusing on the registrational trial for Niyad while deprioritizing the development of pre-filled syringe product candidates due to recent FDA approvals of competing products[36]. - Niyad, a nafamostat product, is classified as a Class III medical device and is undergoing the PMA application process, which is generally more costly and time-consuming than the 510(k) process[64]. - The FDA has 180 days to review a filed PMA application, although the review often takes significantly longer, typically between one and three years[67][68]. - The Breakthrough Devices Program allows for expedited review of devices that provide significant advantages over existing treatments, but does not change the standards for approval[71]. - Post-approval requirements include conducting Phase 4 clinical trials to gain additional experience and ensuring compliance with cGMP requirements[61]. - The FDA may withdraw product approval if compliance with regulatory standards is not maintained, which could lead to severe consequences including product recalls[63]. - Manufacturers must establish validated systems to ensure products meet specifications and regulatory standards, and test each product batch prior to release[62]. - The FDA may require post-approval studies or surveillance to monitor the safety and effectiveness of devices after market release[70]. - The approval process for an NDA is lengthy, and the FDA may issue a Complete Response Letter if the submission does not meet approval criteria[59]. Financial Performance and Concerns - The company has not yet generated significant product revenue and anticipates continued losses in the future[17]. - There is substantial doubt regarding the company's ability to continue as a going concern without raising additional capital[17]. - The market price of the company's common stock has historically been highly volatile, which may affect investor confidence and capital raising efforts[19]. - The company faces significant penalties for violations of health regulatory laws, which could adversely affect operations and financial results[88]. - Sales of product candidates depend on third-party payer coverage and reimbursement, which is increasingly challenging due to cost containment efforts[89]. - Legislative changes, such as the Affordable Care Act and the Inflation Reduction Act, may impact the company's ability to commercialize products profitably[94]. - The company anticipates ongoing pressure to provide larger discounts or rebates to maintain acceptable reimbursement levels[89]. - The pricing of prescription drugs in foreign markets is subject to government control, which may affect profitability[91]. - Future healthcare reforms could limit or eliminate spending on development projects, affecting profitability[93]. - The company may need to conduct expensive pharmacoeconomic studies to demonstrate cost-effectiveness for product approval[89]. Compliance and Legal Matters - Compliance with federal and state healthcare laws, including the Anti-Kickback Statute, is critical to avoid legal scrutiny and potential penalties[78]. - The company is subject to stringent FDA regulations, including quality assurance procedures and medical device reporting regulations[79]. - The company is subject to ongoing legal challenges regarding the Medicare Drug Price Negotiation Program[97]. - There is increasing legislative interest in drug pricing practices, including the Medicare Drug Price Negotiation Program, which began in fiscal year 2023[97]. - The company may face adverse impacts from potential future healthcare reforms that could limit product pricing and reimbursement[98]. Intellectual Property and Market Potential - The company has filed an international patent application for Niyad's use as an anticoagulant, which could provide six years of data exclusivity upon FDA approval[27]. - The company is seeking patent protection for its product candidates, with recent filings expected to extend patent coverage into 2045[47]. - The peak sales potential for Niyad could exceed $200 million annually in the U.S., based on an addressable population of 500,000 patients undergoing CRRT and 350,000 patients undergoing IHD, representing a total market opportunity of $4.075 billion[32]. - Niyad would be the first FDA-approved product for regional anticoagulation in the extracorporeal circuit, targeting the 57% of the market currently using citrate or no anticoagulant[34]. Operational and Employee Matters - The company relies on third-party manufacturers and suppliers for its product candidates, which may pose risks to development timelines[17]. - The company relies on contract manufacturers for the production of Niyad, ensuring a backup manufacturer to avoid supply chain risks[41]. - As of December 31, 2024, the company employed 13 full-time employees, with approximately 85% based in San Mateo, CA[99]. - The company is committed to pay equity and conducts annual pay equity analyses[99]. - The company offers competitive salaries, stock options, and comprehensive benefits to foster employee ownership and development[100]. - There are no collective bargaining agreements in place, and the company maintains a good relationship with its employees[101]. Company Background - The company was incorporated as SuRx, Inc. in 2005 and changed its name to Talphera, Inc. in January 2024[102]. - The company files annual and quarterly reports with the SEC, making them available on its website[102]. - The company is classified as a smaller reporting company and is not required to provide certain financial disclosures[321].